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ABSTRACT
Objectives Our initiative aimed to produce
recommendations on post-randomised controlled trial
(RCT) trial extension studies (TES) reporting using
European League Against Rheumatism (EULAR) standard
operating procedures in order to achieve more
meaningful output and standardisation of reports.
Methods We formed a task force of 22 participants
comprising RCT experts, clinical epidemiologists and
patient representatives. A two-stage Delphi survey was
conducted to discuss the domains of evaluation of a TES
and deﬁnitions. A ‘0–10’ agreement scale assessed each
domain and deﬁnition. The resulting set of
recommendations was further reﬁned and a ﬁnal vote
taken for task force acceptance.
Results Seven key domains and individual components
were evaluated and led to agreed recommendations
including deﬁnition of a TES (100% agreement), minimal
data necessary (100% agreement), method of data
analysis (agreement mean (SD) scores ranging between
7.9 (0.84) and 9.0 (2.16)) and reporting of results as
well as ethical issues. Key recommendations included
reporting of absolute numbers at each stage from the
RCT to TES with reasons given for drop-out at each
stage, and inclusion of a ﬂowchart detailing change in
numbers at each stage and focus (mean (SD) agreement
9.9 (0.36)). A ﬁnal vote accepted the set of
recommendations.
Conclusions This EULAR task force provides
recommendations for implementation in future TES to
ensure a standardised approach to reporting. Use of this
document should provide the rheumatology community
with a more accurate and meaningful output from future
TES, enabling better understanding and more conﬁdent
application in clinical practice towards improving patient
outcomes.
INTRODUCTION
A randomised controlled trial (RCT) is the most
objective means of evaluating an intervention and
underpins regulatory decision-making and, if
appropriate, the introduction of therapies into clin-
ical practice. Many beneﬁts of RCTs have been
seen in the specialty of rheumatology, and
particularly in the management of rheumatoid arth-
ritis (RA).1–10 While the aim of RCTs is to demon-
strate the efﬁcacy and safety of an experimental
agent, their observation period typically spans a
relatively short time frame. However, the use of
therapies in chronic diseases necessitates more
long-term evaluation. The introduction of new
disease modifying anti-rheumatic drug (DMARD)
therapies for the treatment of RA has been asso-
ciated with a signiﬁcant number of post-RCTexten-
sion studies,11–17 henceforth termed ‘trial
extension studies’ (TES), to report the longer-term
outcomes of an experimental agent.
Role of TES
TES can evaluate in particular, the effects of cumu-
lative exposure to a drug, capturing events through
systematic reporting, monitoring of source data,
and consistent coding, thus enabling further assess-
ment of the long-term safety proﬁle observed
during the RCT.18
An additional beneﬁt of TES that is cited is contin-
ued access to an effective but otherwise unlicensed
treatment by RCT participants. However, since a
favourable effect of the treatment may not have been
clearly determined at the time of TES participation
(with results from the preceding RCTand/or indeter-
minate prior studies not available), this raises legitim-
ate ethical issues about the appropriateness of
exposing patients to potentially ineffective or only
partially effective treatments for additional periods of
time.
Challenges of TES
While TES play a valid role, there are clear limita-
tions that should be considered and potential weak-
nesses in the design and method of analysis that
should be addressed.19 TES beneﬁt from the sys-
tematic reporting on cumulative drug exposure but
have clear limitations in the detection of rare and
unexpected events. In addition, selection bias asso-
ciated with TES populations and lack of generalis-
ability are key factors. These issues are discussed in
more detail in the online supplementary material.
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This makes interpretation challenging and sometimes unreli-
able. While guidance for reporting of RCTs20 21 and safety data
from biological DMARD registers22 are available, no recom-
mendations for TES in rheumatology have been published to
date.23 With this in mind, a task force was created with the prin-
cipal aim of developing practical recommendations on key
aspects of TES on the basis of the European League Against
Rheumatism (EULAR) standard operating procedures,24 and
thereby a recommended standardised format for future TES
data reporting to achieve greater transparency. This manuscript
reports the ﬁnal recommendations as agreed by the task force.
METHODS
The task force agreed that a systematic literature review was not
indicated for this initiative, as it would merely serve to further
establish the lack of consistency in TES and emphasise the need
for the development of a standard for future application.25
The target population for these recommendations was chosen
to be rheumatologists, trialists and researchers working in the
ﬁeld of rheumatology, patient organisations and policymakers.
The general approach to this project followed the EULAR stan-
dardised operating procedures for the elaboration and imple-
mentation of evidence-based recommendations.24
The two task force conveners (MHB and MB) set up a multi-
disciplinary task force with participants selected based on their
ﬁeld of expertise, knowledge and experience as well as appro-
priate geographical distribution, primarily across Europe but
also North America.
A ﬁrst meeting of all task force members was convened in
January 2011 to primarily deﬁne the domains for evaluation.
This comprised two breakout sessions, with the task force split
into two groups. Each group had a rapporteur who reported the
outcome to the whole task force. After a ﬁnal round of discus-
sion, the task force agreed on the individual items for inclusion
in a Delphi exercise. The Delphi method offers a consensus
method that is widely used in health service research.26 The
two-step Delphi exercise for this initiative was web based, which
permitted opinions to be provided and votes on the level of
agreement to be cast independently and anonymously.
Geographical limitations were also avoided by this approach. It
was designed by LS-F and reviewed and modiﬁed as indicated
by MHB, LC and MB. Details on how the Delphi exercise was
formulated, responses were scored and the approach for inform-
ing ﬁnal recommendations was devised can be found in the
online supplementary material.
RESULTS
Task force composition
The multidisciplinary task force comprised 22 participants con-
sisting of 17 rheumatologists, of whom six were clinical epide-
miologists and 11 clinical trialists/expert clinicians, two
biostatisticians, one fellow and two patient representatives.
Participants represented 10 European countries, the USA and
Canada.
Response rate
Of the 22 invited experts, three could not attend the ﬁrst
meeting ( January 2011) but were subsequently apprised of the
discussion and participated in the Delphi exercise. One of the
patient representatives could not continue participation after
the ﬁrst meeting. Twenty of the 21 participants responded to
the ﬁrst and all 21 responded to the second Delphi exercise.
The two-step Delphi exercise was completed by January
2012, with subsequent analysis and dissemination of draft
recommendations in March 2012. Final voting took place in
May 2012. However, subsequent steps of involving additional
stakeholders (see ‘Results’ section) and a meeting to discuss the
recommendations ( June 2013) led to a delay in establishing the
recommendations for the purposes of submission. The task
force approved this ﬁnal document that included some modiﬁca-
tions following the last step. More details on the timelines,
responses and involvement of other stakeholders are detailed in
the online supplementary material.
Domains for evaluation
At the initial meeting, the task force agreed on seven main
domains to form the basis of the exercise. These are listed in box 1
with components within each domain that we wished to cover.
Final results
Percentage agreement for each recommendation (following the
second Delphi exercise) is given. Where appropriate, mean (SD)
scores have also been provided. Median (range) scores were also
calculated and are included in the online supplementary material.
Deﬁnition of a TES
▸ Study design deﬁnition (100% agreement): A TES is a study
that follows all patients beyond a pre-speciﬁed trial period
whether the trial was (a) a placebo-controlled RCTwith the
possibility to cross over to an open-label experimental drug
or (b) a placebo-controlled RCTwith the possibility to cross
over to usual care or (c) an active comparator RCT.
▸ Start of a TES (100% agreement): Should be stated in the
pre-speciﬁed protocol with clear justiﬁcation, and should be
at the point of exposure to the experimental drug of interest.
For the experimental randomised arm, this will be the start
of the original RCT, while for those randomised to placebo/
active comparator arm, this point will be on switching to
experimental treatment.
Box 1 The key domains underpinning the Delphi exercise
1. Deﬁnition of a trial extension study (TES)
Study design deﬁnition
Deﬁnition of start of TES
Duration of TES
Patient population of TES
2. Development of a checklist of minimal data items/outcome
necessary for a TES
Minimal information a TES should collect
Elements not amenable to accurate assessment by a TES
Safety elements that may be elicited
Efﬁcacy
3. Additional data/outcomes
Additional legitimate outputs from a TES
4. Method of analysis
5. Method of reporting results
Inclusion of a ﬂowchart
Detail minimal standards by way of a checklist
Frequency and nature of TES
6. Ethics and obtaining consent
7. Over-arching principles
Consultation and stakeholder involvement
General comments on TES and its reporting
Sources of bias and generalisability
Recommendation
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▸ Minimum duration of a TES (100% agreement): It was
agreed by consensus not to deﬁne this; nevertheless, the
rationale for the length chosen should be stated in the pre-
deﬁned protocol with adequate justiﬁcation.
▸ Population for inclusion in a TES (96% agreement): Should
include all patients included in the RCT, with the ability to
separately report on patients who are of speciﬁc interest, for
example, those in remission or with low disease activity.
Checklist of minimal data items/outcome necessary for a TES
Minimal information
The minimal information that should be collected and reported
by a TES is listed in box 2. Minimum and maximum mean (SD)
scores following the ﬁrst Delphi exercise were 7.2 (2.72) and
9.9 (0.36) (refer to the online supplementary material for indi-
vidual mean and median scores) with agreement by 100% of
the task force in the second Delphi exercise.
The entire group also accepted the following statements relat-
ing to the nature of the initial RCT design following the ﬁrst
Delphi exercise:
▸ The minimum data requirements for TES following placebo-
and active comparator RCTs should be the same (93%
agreement).
▸ A TES that follows an active comparator RCT should follow
all randomised patients for the same period of time (not only
patients on the experimental treatment) and including
patients who may switch to an active comparator treatment
(analysed separately) (mean (SD) 7.9 (2.23), median (range)
8.5).2–10
Safety and efﬁcacy outcomes
Evaluation of safety aspects includes several elements, some of
which it may not be feasible to capture within certain study
designs. The following statements were agreed during the ﬁrst
Delphi exercise (minimum and maximum mean score of 7.0
and 8.4; refer to online supplementary material for individual
scores) with 90% accepting all statements in the second round.
Safety
▸ TES may identify new adverse effects that the original RCT
was not able to detect due to greater cumulative drug
exposure.
▸ TES may identify whether the incidence of known adverse
effects changes with longer-term drug exposure.
▸ TES may conﬁrm whether the nature of known adverse
effects identiﬁed from the RCT changes with longer-term
exposure.
▸ TES are sub-optimal to detect rare safety events because they
are not powered for this.
▸ TES are sub-optimal to detect rare safety events because they
include a selected population (responders with likely no pre-
vious serious adverse events).
Efﬁcacy
▸ Greater cumulative exposure to the active drug per patient in
a TES might identify additional information on the drug’s
efﬁcacy.
▸ While deﬁnitions of relapse are currently not available and
require further work, if/when validated, a TES might allow
evaluation of relapse including time to relapse and therefore
the sustainability of original disease control.
Additional data/outcomes
▸ Economic evaluation of long-term treatment with the active
drug may be possible if appropriate measures are recorded in
the TES.
▸ A TES could not accurately evaluate health-related quality of
life.
Method of analysis
Following the second Delphi exercise, this section required
further iterations to reﬁne the initial Delphi statements. These
are detailed in box 3. Minimum and maximum scores of agree-
ment were 7.3 and 9.4 (refer to the online supplementary
material for individual scores).
Method of reporting results
Inclusion of a ﬂowchart
▸ All TES reports should include a ﬂowchart.
This was agreed as a minimal piece of information to accurately
illustrate the treatment arms, and changes in treatment and in
patient numbers during the course of the study (mean (SD) 9.9
(0.36)).
▸ In particular, the absolute measure/count should be reported
(with/without the percentage).
Box 2 Minimal information to be included in a TES report
▸ Progress of subjects at each stage from RCT start to TES
completion with:
– A ﬂow diagram detailing absolute numbers of subjects at
each relevant time-point
– Duration of active treatment
– Time of last observation
▸ All drop-outs detailed
▸ The drop-out rates from each arm during the original RCT
and the cross-over groups
▸ Reason for exclusion from the TES if the patient discontinues
the drug
▸ Reason for cessation of follow-up
▸ Speciﬁcation of reasons for cessation of follow-up other than
adverse event or inefﬁcacy as above, for example,
geographical or doctor-related reasons
▸ Functional status at the time of inclusion in the TES if
applicable
▸ Functional status at last observation if applicable
▸ Disease activity at the time of inclusion in the TES if
applicable
▸ Disease activity at last observation if applicable
▸ For those patients entering the TES having achieved low
disease activity or remission during the RCT, the
sustainability of each disease state should be evaluated and
reported
▸ For those subjects who enter a TES not having achieved
remission/an acceptable disease activity state following the
RCT, the number who achieve this during the TES should be
reported to determine whether longer drug exposure has the
potential to improve the disease state of such subjects
further
▸ Disease-related co-medication (DMARD, corticosteroid) at
each stage from RCT start to TES completion
▸ Any serious adverse events and outcome related to safety at
each stage from RCT start to TES completion
DMARD, disease modifying anti-rheumatic drug; RCT,
randomised controlled trial; TES, trial extension studies.
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In a TES, the denominator of a cohort typically decreases over
time, which results in the reporting of (artiﬁcial) increasing per-
centages of response rates over time.27 The use of absolute
numbers ensures accurate synthesis of the data.
Figure 1 includes a schematic of suggested ﬂowcharts for
either placebo-controlled or active comparator RCTs that was
accepted by the group (mean (SD) 9.0 (2.06)).
Frequency and nature of reporting outputs from a TES
The following recommendations were made (mean scores
between 8.2 and 8.8; refer to the online supplementary material
for individual scores):
▸ Reporting frequency should not be speciﬁed for all TES since
this depends on the research question.
▸ However, the protocol of each TES should pre-specify the
minimum frequency of reports to be written and the basis
for them (purpose, outcomes, length of RCT).
▸ The efﬁcacy and safety results of a TES should generally be
reported together; abstract selection committees and journal
editors should carefully consider reporting of efﬁcacy alone
before acceptance.
Consent
The recommendations related to obtaining consent are detailed
below; this item in particular required speciﬁc input from the
patient representative (refer to the online supplementary
material for individual scores on additional questions that had
means scores of between 6.2–9.4).
▸ All of the subjects undergoing an RCT should be informed
of the importance of long-term surveillance and be given the
opportunity of entering in the long-term follow-up (mean
(SD) 9.4 (0.85)).
▸ Subjects should sign a new consent form both for continu-
ation of the drug and for data collection at that time point
(mean (SD) 7.6 (2.87)).
▸ Annual updates for consent are not recommended (mean
(SD) 3.7 (4.4)).
Over-arching principles
▸ The report of a TES should be consistent with and consolidate
existing established guidelines including CONSORT20 28 and
STROBE29 (mean (SD) score 9.4 (0.85)).
▸ The report of a TES should be consistent with the ACR/
EULAR recommendations on the reporting of clinical trials
in RA21 (mean (SD) score 8.9 (1.88)).
General comments on TES and its reporting
All the following statements were accepted by 95% of the group
in the second Delphi exercise, agreement with the individual
statements having been established as part of the initial Delphi
exercise (agreement score out of 10):
▸ While data linkage is important for long-term observation,
access may be difﬁcult as pharmaceutical companies conduct
most TES; this may in turn limit the overall beneﬁt of such
studies (mean (SD) 7.1 (2.06)).
▸ TES, by deﬁnition, comprise a sub-selected population, not
reﬂective of routine care; hence, even if all patients in an
RCT were entered into a TES, such a study is generalisable
only to patients with similar disease characteristics (mean
(SD) 7.9 (1.76)).
▸ The absence of a clear null hypothesis may make the deﬁn-
ition of comparator groups in a TES difﬁcult (mean (SD) 7.4
(1.74)) and should therefore be stated where appropriate (see
table 3 for details on method of data analysis).
Potential sources of bias or lack of generalisability
Several factors were identiﬁed as possibly inﬂuencing the inclu-
sion of patients in a TES following completion of an RCT,
which could introduce sources of bias and lack of generalisabil-
ity (80% agreement to include all the following statements):
▸ The requirement of a certain level of response (mean (SD)
7.9 (2.67))
▸ The stage of the disease of the patient (mean (SD) 7 (2.18)).
▸ The fact that the investigator is remunerated for each patient
recruited or that the patients may also receive ﬁnancial
Box 3 Guidance on data management and statistical
approach statement
▸ The null hypothesis should be stated at the start where
appropriate.
▸ Multiple comparisons should be taken into account when
determining the level of statistical signiﬁcance.
▸ The null hypothesis should take account of the results of the
original RCT. Depending on the research question, the
results of an RCT should be accommodated in the TES.
▸ The report should comment on cumulative outcome analysis
(beneﬁcial and adverse events) maintaining the original trial
groups, that is, from RCT start not TES start, to avoid
reporting of only the sub-selected patient group that
proceeds to the TES.
▸ The selection bias associated with a TES population means
meaningful non-inferiority/superiority analysis would not be
reliable. The report should focus on how data for sustained
effect from the start to the end of the TES period, within a
single group or the difference between groups was analysed
and whether there was any suggestion of increased effect
(although this could not be subject to formal statistical
testing).
▸ The plan for subjects that drop out of a TES should be
speciﬁed to demonstrate sustained effect from the start to
the end of the TES period. With reducing number of
participants (the denominator), the proportion responding
will artiﬁcially increase if/when the number of patients
(numerator) responding stays the same.
▸ The analysis should include survival/retention rates on
therapy explicitly reporting the number of patients at each
milestone with reasons for change detailed.
▸ A plan on how to analyse this should be included with both
intent-to-treat (ITT) (denominator as the original number
entering the RCT) and completer (those entering TES only)
population analyses reported. A completer analysis should
always be reported together with an ITT analysis.
▸ The repeated measures analysis of the data from a TES in
rheumatology should include the area under the curve of
absolute disease activity (ie, not dichotomous response/
change) preferentially expressed as a score (eg, DAS, SDAI,
etc).
▸ A TES should preferably include hard endpoints (eg, death,
work disability, joint replacement surgery, hospital
admission) from the TES with or without linkages with other
data sources.
RCT, randomised controlled trial; TES, trial extension studies.
The agreement scores were recorded after Delphi round 1.
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compensation and that the drug is free of charge could be of
importance in some health systems (mean (SD) 7.4 (1.7)).
▸ Geographical differences in practice/approach (leading to dif-
ferences in the number and nature of patients included)
(mean (SD) 7.5 (2.45)).
▸ Unwanted heterogeneity from countries where treatment
options may be more limited (eg, patients with higher levels
of disease activity recruited where otherwise only patients in
remission/with low disease activity would be included) (mean
(SD) 7.6 (1.45)).
Consultation on recommendations and stakeholder involvement
The Delphi process established whether input from relevant
stakeholder organisations, namely, industry, regulatory author-
ities (Food and Drug Administration (FDA), European
Medicines Agency (EMA)) and contract research organisations
(CRO) should be sought. In the initial Delphi exercise, 75%
voted in favour of some level of industry input, 94% for regula-
tory authorities and 81% for CRO.
The second Delphi exercise asked for agreement that each of
these organisations be included in the initiative:
▸ Industry and regulatory authority input into the ﬁnal recom-
mendations was recommended, with mean (SD) scores out of
10 of 7.2 (2.48), 8.3 (1.77) and 4.9 (2.85) recorded for the
FDA, EMA and CRO, respectively.
Key industry companies that have been associated with new
drugs in the RA arena were therefore approached (refer to online
supplementary material for details of the companies represented).
DISCUSSION
We present a series of pragmatic recommendations on the
design and reporting of TES in rheumatological conditions
(mainly inﬂammatory arthritis, although the basic principles are
generally applicable), based on a high degree of expert consen-
sus. Our EULAR task force comprised a group of experts
encompassing a range of expertise including clinical trialists,
clinicians experienced in RA treatment, and clinical epidemiolo-
gists as well as patient representatives. A wide range of countries
Figure 1 Schematic of ﬂowcharts for
inclusion in any trial extension study
(TES) report following (A) a
placebo-controlled randomised
controlled trial (RCT) or (B) an active
comparator trial. FU, follow-up; W,
withdrawal. *And loss to follow-up
number. The TES ﬂowchart should
detail the numbers from the start of
the original RCT to the end of the TES.
‘W’ and the vertical dotted line shown
between the RCT and TES phases
denote those subjects who complete
the RCT but opt not to proceed to the
TES. During the RCT and TES, numbers
of early withdrawals and patients
subsequently lost to follow-up should
also be included. (A) In the
placebo-controlled RCT stage, subjects
in the experimental arm who withdraw
and proceed to standard of care, and
in the placebo arm, subjects who
withdraw and proceed to experimental
or standard of care should be included.
(B) Similarly, in the active comparator
trial, subjects in the experimental arm
who withdraw and proceed to
standard of care, and in the active
arm, subjects who withdraw and
proceed to experimental or standard of
care, should be included.
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and health systems were represented, albeit with some omissions
(eg, absence of individuals from Asia), although the opportunity
to evaluate these recommendations in the wider community in
the future should highlight any differing perspectives. With a
generally accepted methodology for prospective observational
studies, we felt an additional systematic review was not neces-
sary and decided to use our expert opinion to formulate guid-
ance for TES. These recommendations complement those
established for clinical trials21 and registries.22
Central to the recommendations was the principle that a TES
report should focus on cumulative outcome analysis, maintaining
the original trial groups to avoid reporting of only the sub-
selected patient group that proceeds to the TES, and thereby
achieve better generalisability of results. Furthermore, the task
force was clear that absolute numbers and not just percentage
response rates should be reported. To facilitate this, we recom-
mend a ﬂow diagram detailing absolute numbers of subjects at
each relevant time point, with clear illustration of drop-outs and
the reason for cessation and/or exclusion at each relevant stage.
While it was agreed that a TES might elaborate on the incidence
and nature of adverse events over time, they are not designed to
capture rare safety signals. TES reports may also have the poten-
tial to inform on the durability of response and the dynamics of
achieving pre-determined targets of treatment (low disease activ-
ity and remission). It was agreed that any analysis should be pre-
speciﬁed in the protocol but should always include an intention
-to-treat in addition to a completer approach. We acknowledge
there are elements that may in particular be the subject of further
discussion in the wider community, for example, the issue of split
reporting. While the task force discouraged this, each case
should be considered individually as there may be instances when
there is utility in this approach to ensure relevant data that is of
interest is disseminated within the public domain.
The recommendations were actively commented on by several
industry companies (see the ‘Consultation of recommendations
and stakeholder involvement’ section) and include their speciﬁc
feedback (which has been indicated directly in the results where
appropriate in the online supplementary material) and as such,
gained the approval of the participating stakeholders. While EMA
representation did not suggest changes to the recommendations, it
acknowledged the importance of standardisation. The interaction
also highlighted how regulatory expectations may drive the indus-
try approach on whether and how TES should be undertaken.
While we acknowledge that the working group was perhaps
relatively small for a consensus exercise, following dissemination
of these recommendations, we would anticipate a subsequent
exercise to capture how they have been received in the wider
rheumatology, trial and industry communities. In future, it will
be important for journal reviewers and editors to measure
future TES reports against the standard set by these recommen-
dations. The future research agenda will include a systematic
review of forthcoming TES to evaluate how well this document
is utilised, with further reﬁnement based on the nature of out-
comes observed. In addition, regulatory agencies may wish to
consider the recommendations and associated issues and how
these may inﬂuence their expectations from industry. This initia-
tive and the interactive session at EULAR, Madrid 2013 with
relevant stakeholders will hopefully be a springboard for further
action (the outcome of the EULAR meeting is summarised in
the online supplementary material).
In summary, there is a clear unmet need for a reliable
approach to the reporting of TES to maximise our understand-
ing of drug effects in chronic conditions. This initiative, its prin-
ciples and resulting recommendations apply to TES for any
drug in RA as well as for drugs used to treat other chronic
rheumatological conditions. This document provides much
needed ﬁrst recommendations to ensure a transparent and stan-
dardised approach to the reporting of future TES.
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